These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34130575)

  • 1. The impact of the COVID-19 pandemic on addressing common barriers to pharmacy-based point-of-care testing.
    Klepser DG; Klepser NS; Adams JL; Adams AJ; Klepser ME
    Expert Rev Mol Diagn; 2021 Aug; 21(8):751-755. PubMed ID: 34130575
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacy-based CLIA-waived testing in the United States: Trends, impact, and the road ahead.
    Zalupski B; Elroumi Z; Klepser DG; Klepser NS; Adams AJ; Klepser ME
    Res Social Adm Pharm; 2024 Jun; 20(6):146-151. PubMed ID: 38519341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential for Pharmacy-Public Health Collaborations Using Pharmacy-Based Point-of-Care Testing Services for Infectious Diseases.
    Gubbins PO; Klepser ME; Adams AJ; Jacobs DM; Percival KM; Tallman GB
    J Public Health Manag Pract; 2017; 23(6):593-600. PubMed ID: 27997479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular point-of-care testing in the community pharmacy setting: current status and future prospects.
    Klepser M; Koski RR
    Expert Rev Mol Diagn; 2022 Oct; ():1-14. PubMed ID: 36269237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of CLIA-waived point-of-care tests for infectious diseases in community pharmacies in the United States.
    Weber NC; Klepser ME; Akers JM; Klepser DG; Adams AJ
    Expert Rev Mol Diagn; 2016; 16(2):253-64. PubMed ID: 26560318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Point-of-care testing for infectious diseases: opportunities, barriers, and considerations in community pharmacy.
    Gubbins PO; Klepser ME; Dering-Anderson AM; Bauer KA; Darin KM; Klepser S; Matthias KR; Scarsi K
    J Am Pharm Assoc (2003); 2014; 54(2):163-71. PubMed ID: 24632931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community Pharmacists: On the frontline of health service against COVID-19 in LMICs.
    Hedima EW; Adeyemi MS; Ikunaiye NY
    Res Social Adm Pharm; 2021 Jan; 17(1):1964-1966. PubMed ID: 32317154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point-of-Care Testing in Community Pharmacies: Keys to Success From Pennsylvania Pharmacists.
    Steltenpohl EA; Barry BK; Coley KC; McGivney MS; Olenak JL; Berenbrok LA
    J Pharm Pract; 2018 Dec; 31(6):629-635. PubMed ID: 29034781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacy-Based Infectious Disease Management Programs Incorporating CLIA-Waived Point-of-Care Tests.
    Herbin SR; Klepser DG; Klepser ME
    J Clin Microbiol; 2020 Apr; 58(5):. PubMed ID: 32075903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient awareness, willingness, and barriers to point-of-care hepatitis C screening in community pharmacy.
    Brewer A; Hanna C; Eckmann L; Schadler A; Divine H
    J Am Pharm Assoc (2003); 2018; 58(4S):S69-S72.e1. PubMed ID: 30006188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Provision of clinical pharmacy services during the COVID-19 pandemic: Experiences of pharmacists from 16 European countries.
    Paudyal V; Cadogan C; Fialová D; Henman MC; Hazen A; Okuyan B; Lutters M; Stewart D
    Res Social Adm Pharm; 2021 Aug; 17(8):1507-1517. PubMed ID: 33288420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maintaining point of care testing capacity and pandemic preparedness in the post-COVID-19 era.
    Rakeman-Cagno JL; Persing DH; Loeffelholz MJ
    Expert Rev Mol Diagn; 2024 Mar; 24(3):147-151. PubMed ID: 37724428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of pharmacist-provided point of care testing.
    Kuhn CH
    J Am Pharm Assoc (2003); 2015; 55(6):572-573. PubMed ID: 26547594
    [No Abstract]   [Full Text] [Related]  

  • 14. Community pharmacy-based point-of-care testing: A case study of pharmacist-physician collaborative working relationships.
    Bacci JL; Klepser D; Tilley H; Smith JK; Klepser ME
    Res Social Adm Pharm; 2018 Jan; 14(1):112-115. PubMed ID: 28082033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholesterol Point-of-Care Testing for Community Pharmacies: A Review of the Current Literature.
    Haggerty L; Tran D
    J Pharm Pract; 2017 Aug; 30(4):451-458. PubMed ID: 27121870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implementation of Preoperative Screening Protocols in Otolaryngology During the COVID-19 Pandemic.
    Urban MJ; Patel TR; Raad R; LoSavio P; Stenson K; Al-Khudari S; Nielsen T; Husain I; Smith R; Revenaugh PC; Wiet RM; Papagiannopoulos P; Batra PS; Tajudeen BA
    Otolaryngol Head Neck Surg; 2020 Aug; 163(2):265-270. PubMed ID: 32452746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community pharmacy during the COVID-19 pandemic: a cross-sectional study.
    Merks P; Świeczkowski D; Bilmin K; Jakubowska M; Drelich E; Lewicki J; Gołębiewska W; Bogusz J; Jaguszewski M
    Przegl Epidemiol; 2020; 74(4):620-633. PubMed ID: 33861029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A state-level needs analysis of community pharmacy point-of-care testing.
    Gallimore CE; Porter AL; Barnett SG; Portillo E; Zorek JA
    J Am Pharm Assoc (2003); 2021; 61(3):e93-e98. PubMed ID: 33431252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surviving the surge: Evaluation of early impact of COVID-19 on inpatient pharmacy services at a community teaching hospital.
    McConachie S; Martirosov D; Wang B; Desai N; Jarjosa S; Hsaiky L
    Am J Health Syst Pharm; 2020 Nov; 77(23):1994-2002. PubMed ID: 32469045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alaska pharmacists: First responders to the pandemic in the last frontier.
    Paul AK; Bogart T; Schaber AR; Cutchins DC; Robinson RF
    J Am Pharm Assoc (2003); 2021; 61(1):e35-e38. PubMed ID: 33036935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.